Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
| Revenue (TTM) | $830.44M |
| Gross Profit (TTM) | $605.31M |
| EBITDA | $110.43M |
| Operating Margin | -2.49% |
| Return on Equity | -10.50% |
| Return on Assets | 0.39% |
| Revenue/Share (TTM) | $14.46 |
| Book Value | $17.73 |
| Price-to-Book | 2.48 |
| Price-to-Sales (TTM) | 3.05 |
| EV/Revenue | 2.678 |
| EV/EBITDA | 51.86 |
| Quarterly Earnings Growth (YoY) | 11.10% |
| Quarterly Revenue Growth (YoY) | 32.40% |
| Shares Outstanding | $58.13M |
| Float | $51.65M |
| % Insiders | 4.33% |
| % Institutions | 106.58% |
Volatility is currently contracting
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will encourage others to advocate for their health and initiate collaborative conversations with their doctors about a potential treatment plan.
Investors need to pay close attention to SUPN stock based on the movements in the options market lately.
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.
EDRY, OPBK, SUPN, MSBI and NXRT have been added to the Zacks Rank #1 (Strong Buy) List on August 7th, 2026.
BCAL, SUPN and NXRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 7th, 2026.
Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SUPN and any ticker you trade — then tracks every position and per-strategy win rate.
